“Durability of Efficacy and Safety of Roflumilast Cream 0.3% in Adults With Chronic Plaque Psoriasis From a 52-Week, Phase 2 Open-Label Safety Trial”. SKIN The Journal of Cutaneous Medicine, vol. 7, no. 4, July 2023, p. s218, https://doi.org/10.25251/skin.7.supp.218.